Vertex has doubled down on cell-based therapies for type 1 diabetes (T1D), buying ViaCyte in a $320 million deal that it says will accelerate development of its own candidate VX-880. The deal has ...
Today is the final day of Walmart’s Super Savings Week. The week-long, online-only sale has featured lots of deals on ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback